PMID- 10567680
OWN - NLM
STAT- MEDLINE
DCOM- 20000110
LR  - 20190516
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 4
IP  - 6
DP  - 1999 Dec
TI  - A cytogenetic and fluorescence in situ hybridization evaluation of 
      interferon-alpha in the treatment of chronic myeloid leukemia.
PG  - 659-63
AB  - The effect of interferon-alpha (IFN) for chronic myeloid leukemia (CML) in the 
      chronic phase (CP) was retrospectively evaluated in comparison with that of 
      busulfan (BU) or hydroxyurea (HU) given alone. Among 107 patients diagnosed with 
      CML between 1982 and 1997, 72 CP cases evaluable for long-term follow-up included 
      13 patients treated with BU alone, 18 with HU alone, and 41 with IFN-based 
      therapy. Complete cytogenetic response (CCR) was achieved in 4/41 IFN cases 
      (10%), and partial or minimal cytogenetic response occurred in 18/41 IFN cases 
      (44%). In contrast, no cytogenetic response (NCR) was achieved in any BU or HU 
      case. IFN treatment for 6 to 60 months was needed to achieve CCR. Overall 
      survival curves revealed that the IFN group had significantly better survival 
      than BU and HU groups (p=0.008 and 0.04, respectively). A significant correlation 
      was found between karyotypic findings and fluorescence in situ hybridization 
      (FISH) analyses in IFN-treated cases (r=0.739, p=0.0001). In some cases, however, 
      the two methods showed discrepancy; BCR/ABL-positive cells represented only 
      20-75% of interphase bone marrow cells in NCR cases, although all metaphases 
      examined were positive for the Philadelphia chromosome (Ph). A discrepancy was 
      also seen in CCR cases; up to 22% of cells assessed were BCR/ABL-positive. These 
      findings suggest that IFN is a useful therapy for CML in CP, and may have a 
      suppressive effect on the CML clone even in NCR cases. The results also indicate 
      that a combination of FISH and cytogenetic analyses may provide more detailed 
      information for evaluating the efficacy of IFN than conventional cytogenetics 
      alone.
FAU - Itoh, T
AU  - Itoh T
AD  - Second Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, 
      Hyogo 663-8501, Japan.
FAU - Tamura, S
AU  - Tamura S
FAU - Takemoto, Y
AU  - Takemoto Y
FAU - Kakishita, E
AU  - Kakishita E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interferon-alpha)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aneuploidy
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Bone Marrow/pathology
MH  - Female
MH  - Fusion Proteins, bcr-abl/analysis/genetics
MH  - Humans
MH  - Hydroxyurea/therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - *In Situ Hybridization, Fluorescence
MH  - Interferon-alpha/*therapeutic use
MH  - *Karyotyping
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/genetics/mortality/*therapy
MH  - Life Tables
MH  - Male
MH  - Middle Aged
MH  - Neoplastic Stem Cells/chemistry/ultrastructure
MH  - Philadelphia Chromosome
MH  - Survival Rate
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.3892/ijmm.4.6.659 [doi]
PST - ppublish
SO  - Int J Mol Med. 1999 Dec;4(6):659-63. doi: 10.3892/ijmm.4.6.659.